UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure
- Tom A Yates1,
- Karthikeyan Paranthaman1,
- Ly-Mee Yu2,
- Elizabeth Davis1,
- Sarah Lang3,
- Scott J Hackett4,
- Steven B Welch4,
- Andrew J Pollard1,5,
- Matthew D Snape1,5
- 1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
- 2Centre for Statistics in Medicine, University of Oxford, Oxford, UK
- 3Thames Valley Health Protection Unit, Centre for Radiation, Chemical and Environmental Hazards, Chilton, UK
- 4Department of Paediatrics, Birmingham Heartlands Hospital, Birmingham, UK
- 5NIHR Oxford Biomedical Research Centre, Oxford, UK
- Correspondence to Dr Tom Yates, Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK;
- Received 11 April 2012
- Revised 24 January 2013
- Accepted 28 January 2013
- Published Online First 9 March 2013
Objective To assess persistence of immunity to hepatitis B (HBV) in primary school children vaccinated following perinatal exposure.
Design Serological survey.
Setting Five UK sites (Berkshire East, Birmingham, Buckinghamshire, Milton Keynes and Oxfordshire).
Participants Children from 3 years 4 months to 10 years of age (mean age 6.2 years), vaccinated against HBV from birth following perinatal exposure.
Interventions A single booster dose of the paediatric formulation of a recombinant HBV vaccine.
Main outcome measures Titres of antibody against hepatitis B Surface Antigen (anti-HBs) measured immediately before and 21–35 days after the HBV vaccine booster.
Results Prebooster anti-HBs titres were >10 mIU/ml in 84.6% of children (n=26; 95% CI 65.1 to 95.6%). All children (n=25, 95% CI 86.3 to 100%) had titres >100 mIU/ml after the booster.
Conclusions This study of antibody persistence among UK children born to hepatitis B infected women, immunised with a 3-dose infant schedule with a toddler booster suggests sustained immunity through early childhood. These data should prompt further studies to address the need for a preschool booster.
Trial registration Eudract Number 2008-004785-98.